Literature DB >> 14667276

Sodium-wasting nephropathy caused by cisplatin in a patient with small-cell lung cancer.

Akila V Iyer1, Steven H Krasnow, D Robert Dufour, Anthony S Arcenas.   

Abstract

We describe a case of severe hyponatremia following chemotherapy administration in a patient with small-cell lung cancer. There was no evidence of the syndrome of inappropriate antidiuretic hormone (SIADH) secretion. The clinical and laboratory findings were consistent with a sodium-wasting nephropathy complicating cisplatin administration. There are few well-documented reports of cisplatin-associated hyponatremia in the medical literature. We have summarized the relevant literature and attempted to define the differential diagnosis of hyponatremia in this setting. Most cases are accounted for by sodium-losing nephropathy of SIADH, but many reported cases contain insufficient data for classification. Appropriate attention to the evaluation of hyponatremia following platinum-based chemotherapy is needed to properly treat these conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14667276     DOI: 10.3816/CLC.2003.n.033

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  10 in total

1.  Voriconazole-associated salt-losing nephropathy.

Authors:  Junya Teranishi; Katsuyuki Nagatoya; Tomoko Kakita; Yoko Yamauchi; Hirohisa Matsuda; Tatsuhiko Mori; Toru Inoue
Journal:  Clin Exp Nephrol       Date:  2010-06-22       Impact factor: 2.801

Review 2.  Diagnosis and management of hyponatremia in cancer patients.

Authors:  Harry Raftopoulos
Journal:  Support Care Cancer       Date:  2007-08-14       Impact factor: 3.603

Review 3.  Tumor-related hyponatremia.

Authors:  Adedayo A Onitilo; Ebenezer Kio; Suhail A R Doi
Journal:  Clin Med Res       Date:  2007-12-17

4.  Hyponatremia in patients with esophageal cancer treated with chemotherapy including cisplatin.

Authors:  Ayako Shimada; Hiroya Takeuchi; Kazumasa Fukuda; Koichi Suda; Rieko Nakamura; Norihito Wada; Hirofumi Kawakubo; Yuko Kitagawa
Journal:  Esophagus       Date:  2018-04-27       Impact factor: 4.230

Review 5.  A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia.

Authors:  Ranpu Wu; Chuling Li; Zimu Wang; Hang Fan; Yong Song; Hongbing Liu
Journal:  Transl Lung Cancer Res       Date:  2020-12

6.  Validity of Weekly Administration of Carboplatin after Carboplatin-Induced SIADH: Two Case Reports and Literature Review.

Authors:  Suguru Fujitsuka; Naoki Horikawa; Teruki Yoshida; Sae Yu; Ryosuke Kuroda; Mitsuru Tsuji; Maki Umemiya; Rei Gou; Yoshihide Inayama; Hirohiko Tani; Kenzo Kosaka
Journal:  Case Rep Oncol       Date:  2022-03-03

7.  Hyponatremia in the intensive care unit: How to avoid a Zugzwang situation?

Authors:  Cédric Rafat; Martin Flamant; Stéphane Gaudry; Emmanuelle Vidal-Petiot; Jean-Damien Ricard; Didier Dreyfuss
Journal:  Ann Intensive Care       Date:  2015-11-09       Impact factor: 6.925

8.  A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan.

Authors:  Claudia Petereit; Okan Zaba; Ishak Teber; Heike Lüders; Christian Grohé
Journal:  BMC Pulm Med       Date:  2013-08-29       Impact factor: 3.317

Review 9.  Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives.

Authors:  Bijin Thajudeen; Abdulla K Salahudeen
Journal:  Cancer Manag Res       Date:  2016-08-22       Impact factor: 3.989

10.  The role of tolvaptan in managing hyponatremia in small cell lung cancer patients with SIADH: a retrospective study of 23 cases.

Authors:  Peng Ren; Qiuan Yang
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.